XDEMVY is a topical ophthalmic formulation of lotilaner that, if approved, may offer treatment for millions of patients with MGD.1
Many people with dry eye suffer from MGD, a disease that has been linked to the presence of Demodex mites.2-5
*XDEMVY is only FDA approved for the treatment of Demodex blepharitis. XDEMVY is currently being investigated in a Phase 2a trial for MGD.
1. Tarsus initiates phase 2a Ersa trial evaluating TP-03 for the treatment of meibomian gland disease. News release. Tarsus Pharmaceuticals, Inc. August 5, 2022. Accessed August 11, 2023. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-treatment 2. Sun M, Moreno IY, Dang M, Coulson-Thomas VJ. Meibomian gland dysfunction: what have animal models taught us? Int J Mol Sci. 2020;21(22):8822. 3. Hauser W. How to answer the “why?” of dry eye. Review of Optometry. Published November 15, 2020. Accessed August 11, 2023. https://www.reviewofoptometry.com/article/how-to-answer-the-why-of-dry-eye 4. Zhang XB, Ding YH, He W. The association between Demodex infestation and ocular surface manifestations in meibomian gland dysfunction. Int J Ophthalmol. 2018;11(4):589-502. 5. Amescua G, Akpek EK, Farid M, et al. Blepharitis Preferred Practice Pattern®. American Academy of Ophthalmology. Published October 23, 2018. Accessed August 11, 2023. https://www.aaojournal.org/article/S0161-6420(18)32645-9/pdf 6. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea. 2022;42:435-443. 7. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023.
Please reach out to us using the form below.
"*" indicates required fields